D. Evans

D. Evans, L. Barr, D. Evans, 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Current Policies for Surveillance and Management in Women at Risk for Breast and Ovarian Cancer: A Survey among 16 European Family Cancer Clinics

J. Chang-Claude, P. Møller, D. Eccles, 2002, Disease Markers.

Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.

J. Chang-Claude, P. Møller, D. Eccles, 1998, European journal of cancer.

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study

R. Eeles, D. Easton, S. Lakhani, 2018, The Lancet. Oncology.

Guidelines for a genetic risk based approach to advising women with a family history of breast cancer

D. Eccles, D. Evans, J. Mackay, 2000, Journal of medical genetics.

Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer research.

Modification of BRCA 1-Associated Breast and Ovarian Cancer Risk by BRCA 1-Interacting Genes

F. Couch, O. Olopade, T. Rebbeck, 2011 .

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

D. Steinemann, F. Couch, O. Olopade, 2017, Journal of Clinical Oncology.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2014, Breast Cancer Research.

Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2015 .

Non-random transmission of mutant alleles to female offspring in BRCA carriers

D. Evans, A. Shenton, S. Sharif, 2005, Journal of Medical Genetics.

Prostate Cancer Risk by BRCA2 Genomic Regions

R. Eeles, D. Easton, A. Antoniou, 2020, European urology.

Identification of Novel Genetic Markers of Breast Cancer Survival

Peter Kraft, Nazneen Rahman, Janet A. Dunn, 2015, Journal of the National Cancer Institute.

Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort

D. Evans, D. Halliday, R. Jena, 2016, Journal of Neuro-Oncology.

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study☆

R. Eeles, D. Easton, A. Antoniou, 2020, European urology.

Optimal selection of individuals for BRCA mutation testing.

D. Evans, F. Lalloo, D. Eccles, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status

R. Eeles, D. Easton, A. Antoniou, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Rare copy number variants (CNVs) and breast cancer risk

Jack A. Taylor, S. Cross, M. Beckmann, 2021, bioRxiv.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers

D. Evans, N. Basu, D. Evans, 2016 .

The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case–control study

J. Cuzick, A. Howell, D. Evans, 2016, Journal of Medical Genetics.

Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis

A. Howell, D. Evans, J. Hodson, 2015, Familial Cancer.

Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies

A. Howell, D. Evans, E. Harkness, 2014, Journal of Medical Genetics.

Increased Rate of Phenocopies in All Age Groups in BRCA1/BRCA2 Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to BRCA2 Mutation Carriers

I. Buchan, A. Howell, D. Evans, 2013, Cancer Epidemiology, Biomarkers and Prevention.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

J. S. Hoffman, W. Chung, V. Pankratz, 2012, Human mutation.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers

Joshua M. Korn, M. Daly, D. Altshuler, 2011, Human Genetics.

University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch,

F. Couch, B. Bonanni, O. Olopade, 2013 .

q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012 .

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers

O. Olopade, T. Rebbeck, R. Eeles, 2011 .

Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens

A. Howell, D. Evans, S. Verhoef, 2016, Breast Cancer Research and Treatment.

Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

F. Couch, T. Rebbeck, J. Benítez, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women

D. Evans, D. French, N. Qureshi, 2019, Journal of medical screening.

Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds

P. Møller, E. Hovig, D. Vodák, 2018, Hereditary Cancer in Clinical Practice.

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

R. Eeles, J. Hopper, D. Easton, 2021, American journal of obstetrics and gynecology.

Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy

A. Howell, K. Heimdal, P. Møller, 2002, International journal of cancer.

Fine-Mapping CASP8 Risk Variants in Breast Cancer

Ryan Abo, Stacey Knight, Angela Cox, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Karlan, J. Benítez, 2011, Journal of the National Cancer Institute.

Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1

Jonathan Green, D. Evans, C. Stagg, 2021, Scientific Reports.

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

W. Chung, D. Steinemann, F. Couch, 2019, British Journal of Cancer.

Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database

Aung Ko Win, P. Møller, E. Hovig, 2019, Genetics in Medicine.

Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome

D. Evans, Julie Morris, F. Lalloo, 2017, JAMA oncology.

Variants in CHEK 2 Other than 1100 delC Do Not Make a Major Contribution to Breast Cancer Susceptibility

S. Seal, M. Stratton, N. Rahman, 2003 .

Neurofibromatosis type 2 discordance in monozygous twins

D. Evans, A. Wallace, S. Tobi, 2020, Familial Cancer.

Neurofibromatosis type 2 and related disorders.

D. Evans, D. Halliday, A. Parry, 2019, Current opinion in oncology.

Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing

D. Evans, D. Halliday, M. Kellett, 2019, Genetics in Medicine.

Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity

D. Evans, D. Halliday, James Nicholson, 2019, Clinical genetics.

Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing

D. Evans, D. Halliday, M. Kellett, 2018, Genetics in Medicine.

Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene

D. Evans, M. Kellett, S. Rutherford, 2018, The Laryngoscope.

Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient

D. Evans, D. Halliday, M. Kellett, 2018, Neurosurgery.

Cranial irradiation in childhood mimicking neurofibromatosis type II

D. Evans, S. Constantini, S. Ben-Shachar, 2017, American journal of medical genetics. Part A.

Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis

D. Evans, S. Rutherford, A. Wallace, 2017, Neurology.

Bilateral vestibular schwannomas in older patients: NF2 or chance?

D. Evans, S. Huson, R. Ramsden, 2015, Journal of Medical Genetics.

Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis

D. Evans, A. Samii, D. Halliday, 2015, Neurology.

Recommendations for imaging tumor response in neurofibromatosis clinical trials

B. Korf, D. Evans, G. Harris, 2013, Neurology.

Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2

D. Evans, R. Ramsden, S. Rutherford, 2013, British journal of neurosurgery.

Neurofibromatoses in Clinical Practice

D. Evans, S. Huson, R. Ferner, 2011 .

Empirical development of improved diagnostic criteria for neurofibromatosis 2

D. Evans, R. Ramsden, A. Shenton, 2011, Genetics in Medicine.

Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset

D. Evans, D. Halliday, S. Huson, 2011, Journal of Medical Genetics.

Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas

D. Evans, W. Newman, S. Rutherford, 2010, Oncogene.

Outcome from surgery for vestibular schwannomas in children

D. Evans, R. Ramsden, S. Rutherford, 2009, British journal of neurosurgery.

Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification

D. Evans, S. Huson, R. Ramsden, 2007, Journal of Medical Genetics.

News on the genetics, epidemiology, medical care and translational research of Schwannomas

D. Evans, C. Hanemann, D. Evans, 2006, Journal of Neurology.

Increasing the specificity of diagnostic criteria for schwannomatosis

D. Evans, M. Baser, J. Friedman, 2006, Neurology.

D. Evans, M. Baser, E. Maher, 2005, Journal of Medical Genetics.

The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2

D. Evans, C. Lázaro, G. Rouleau, 2005, Journal of Medical Genetics.

Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2

D. Evans, V. Mautner, M. Baser, 2005, Journal of Medical Genetics.

Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2

D. Evans, R. de Silva, M. Baser, 2004, Journal of Medical Genetics.

Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation

D. Evans, J. Varley, R. Ramsden, 2003, Journal of medical genetics.

Evaluation of clinical diagnostic criteria for neurofibromatosis 2

D. Evans, R. Ramsden, M. Baser, 2002, Neurology.

Predictors of the risk of mortality in neurofibromatosis 2.

D. Evans, R. Ramsden, Dana Aeschliman, 2002, American journal of human genetics.

Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas

D. Evans, A. Read, R. Ramsden, 2002, Journal of medical genetics.

Lack of sex-ratio distortion in neurofibromatosis 2.

D. Evans, M. Baser, D. Evans, 2000, American journal of medical genetics.

Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma

R T Ramsden, D. Evans, T. Strachan, 1999, Journal of neurology, neurosurgery, and psychiatry.

Neurofibromatosis Type 2: Genetic and Clinical Features

D. Evans, D. Evans, D. Evans, 1999, Ear, nose, & throat journal.

Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.

D. Evans, A. Read, R. Ramsden, 1998, Journal of medical genetics.

Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.

D. Evans, T. Strachan, R. Ramsden, 1998, American journal of human genetics.

Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.

D. Evans, E. Bijlsma, A. Wallace, 1997, Journal of medical genetics.

A clinical, genetic and audiological study of patients and families with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas

D. Evans, T. Strachan, R. Ramsden, 1996, The Journal of Laryngology & Otology.

Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis

D. Evans, D. Donnai, A. Colley, 1996, Clinical genetics.

Diagnostic issues in a family with late onset type 2 neurofibromatosis.

D. Evans, T. Strachan, R. Ramsden, 1995, Journal of medical genetics.

Heterogeneity in genetic conditions.

D. Evans, R. Harris, D. Evans, 1992, The Quarterly journal of medicine.

Chapter 2 Neurofibromatosis Type 2 ( NF 2 )

D. Evans, D. Evans, D. Evans, 2019 .

Neurofibromatosis Type 2 (NF2)

D. Evans, D. Evans, D. Evans, 2011 .

What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors?

D. Evans, S. Huson, R. Ramsden, 2008, Journal of neurosurgery.

Chapter 5 Neurofibromatosis type 2

D. Evans, D. Evans, D. Evans, 2022 .

Gene-gene interactions in breast cancer susceptibility.

Deborah Hughes, Peter Donnelly, Jonathan Berg, 2012, Human molecular genetics.

Breast Cancer and BRCA1 and BRCA2 Pathogenic Variants

D. Evans, N. Basu, D. Evans, 2020, Breast Cancer and Breast Reconstruction.

Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status

A. Howell, P. Møller, D. Evans, 2007, International journal of cancer.

BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries

D. Evans, F. Lalloo, A. Wallace, 2010, Journal of Medical Genetics.

Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing

P. Møller, E. Hovig, D. Vodák, 2019, Scientific Reports.

Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort

R. Eeles, D. Evans, M. Watson, 2002, British Journal of Cancer.

Childhood predictive genetic testing for Li–Fraumeni syndrome

R. Eeles, D. Evans, T. Clancy, 2010, Familial Cancer.

Genetic and cytogenetic studies in inherited cancer: Li Fraumeni syndrome

D. Evans, J. Varley, J. Boyle, 2000 .

Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2

S. Seal, N. Rahman, D. Noh, 2012, PloS one.

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases

G. Jayson, D. Evans, G. Burghel, 2019, Journal of Medical Genetics.

Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

A. Howell, D. Evans, S. Howell, 2019, Familial Cancer.

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

A. Howell, D. Evans, F. Lalloo, 2010, British Journal of Cancer.

Breast cancer risks associated with missense variants in breast cancer susceptibility genes

M. Beckmann, N. Camp, Jingmei Li, 2021, medRxiv.

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

D. Easton, J. Hopper, D. Easton, 2005, Journal of Medical Genetics.

Vestibular schwannoma: role of conservative management

D. Evans, R. Ramsden, J. Gillespie, 2010 .

Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study

R. Eeles, F. Gilbert, D. Evans, 2011, British journal of cancer.

Breast cancer risk feedback to women in the UK NHS breast screening population

I. Buchan, S. Astley, J. Cuzick, 2016, British Journal of Cancer.

Global burden of childhood and adolescent cancer.

D. Evans, E. Woodward, D. Evans, 2020, Chinese clinical oncology.

Low Lifetime Risk of Contralateral Breast Cancer in a Middle-Income Asian Country: Evidence to Guide Post-treatment Surveillance

D. Evans, C. Yip, N. Taib, 2018, World Journal of Surgery.

Uptake of breast cancer prevention and screening trials

A. Howell, D. Evans, N. Bundred, 2010, Journal of Medical Genetics.

Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

S. Cross, M. Beckmann, P. Fasching, 2021, Breast Cancer Research.

Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome

W. Foulkes, D. Evans, K. Nathanson, 2017, Clinical Cancer Research.

Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC)

D. Evans, D. Buchanan, F. Lalloo, 2014, Journal of Medical Genetics.

The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study

D. Evans, I. Frayling, E. Crosbie, 2020, PLoS medicine.

Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome.

B. Ponder, D. Evans, S. Hodgson, 1996, Journal of medical genetics.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers

F. Couch, O. Olopade, T. Rebbeck, 2010, Breast Cancer Research and Treatment.

UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants

R. Eeles, D. Evans, A. Sohaib, 2020, Journal of Medical Genetics.

Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY)

R. Whitehouse, R. Eeles, E. Page, 2019, Journal of Medical Genetics.

A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients

A. Howell, D. Evans, J. Birch, 2002, British Journal of Cancer.

Neurofibromatosis Type 1 and Autism Spectrum Disorder

R. Emsley, Jonathan Green, D. Evans, 2013, Pediatrics.

The Manchester guidelines for contralateral risk-reducing mastectomy

D. Evans, L. Barr, N. Basu, 2015, World Journal of Surgical Oncology.

Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England.

D. Evans, L. Barr, N. Basu, 2016, Annals of the Royal College of Surgeons of England.

Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.

A. Howell, D. Evans, F. Lalloo, 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.